$5.12
▲ +$0.23
(+4.70%)
Vol 108K
4
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$60.7M
ROE
-322.2%
Margin
-14250.5%
D/E
636.05
Beta
0.80
52W
$2–$14
Wall Street Consensus
12 analysts · Apr 20262
Strong Buy
9
Buy
1
Hold
0
Sell
0
Strong Sell
91.7%
Buy Rating
Price Chart
Similar Stocks
Earnings
Beat rate: 25.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-0.60 | $-0.88 | $-0.28 |
| Sep 2025 | $-0.59 | $-0.85 | $-0.26 |
| Jun 2025 | $-0.48 | $-0.78 | $-0.30 |
| Mar 2025 | $-0.97 | $-0.09 | +$0.88 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Revenue | — | $91K | $81K | $27K | $15K | $77K |
| Net Income | — | -$13.5M | -$751K | -$7.4M | -$8.8M | -$9.2M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | — | -322.2% | -322.2% | -322.2% | -322.2% | -322.2% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -27477.8% | -10386.4% | -10386.4% | -10386.4% | -10386.4% | -14250.5% |
| Gross Margin | 100.0% | 80.4% | 80.4% | 80.4% | 80.4% | 82.2% |
| D/E Ratio | — | 636.05 | 636.05 | 636.05 | 636.05 | 636.05 |
| Current Ratio | 1.58 | 1.58 | 1.58 | 1.58 | 1.58 | 1.53 |
Key Ratios
ROA (TTM)
-125.6%
P/S (TTM)
283.46
P/B
2.8
EPS (TTM)
$-3.33
CF/Share
$-0.43
Rev Growth 3Y
-22.0%
52W High
$13.50
52W Low
$2.28
$2.28
52-Week Range
$13.50
Financial Health
Free Cash Flow
-$4.8M
Net Debt
$16.5M
Cash
$5.2M
Total Debt
$21.7M
As of Dec 31, 2025
How does CLNN compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
CLNN valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
283.5
▲
2106%
above
peers
(12.9)
vs Peers
vs Industry
Pricier
P/B ratio
2.8
▲
16%
above
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
CLNN profitability vs Biotechnology peers
ROE
-322.2%
▼
379%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
-14250.5%
▼
4870%
below
peers
(-286.8%)
vs Peers
vs Industry
Weak
Gross margin
82.2%
▲
5%
above
peers
(78.6%)
vs Peers
vs Industry
Weak
ROA
-125.6%
▼
169%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
CLNN financial health vs Biotechnology peers
D/E ratio
636.1
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
High debt
Current ratio
1.5
▼
66%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
0.8
▼
17%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
CLNN fundamentals radar
CLNN
Peer median
Industry
CLNN profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
CLNN vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
UGWUMBA CHIDOZIE
Beneficial Owner of more than… · Mar 26
17909 shs
UGWUMBA CHIDOZIE
Beneficial Owner of more than… · Feb 03
5559 shs
UGWUMBA CHIDOZIE
Beneficial Owner of more than… · Feb 02
24770 shs
UGWUMBA CHIDOZIE
Beneficial Owner of more than… · Jan 28
19274 shs
UGWUMBA CHIDOZIE
Beneficial Owner of more than… · Jan 23
18221 shs
UGWUMBA CHIDOZIE
Beneficial Owner of more than… · Jan 21
32474 shs
UGWUMBA CHIDOZIE
Beneficial Owner of more than… · Jan 15
58289 shs
MOSCA ALISON
Director · Jan 13
16667 shs
MATLIN DAVID J.
Director · Jan 13
33333 shs
UGWUMBA CHIDOZIE
Beneficial Owner of more than… · Jan 12
44975 shs
Last 90 days
Top Holders
Top 5: 13.43%SymBiosis Capital Partners,…
6.54%
$3.6M
Scoggin Management, LP
2.33%
$1.3M
Vanguard Group Inc
1.89%
$1.0M
Boxer Capital Management, L…
1.70%
$941K
Ensign Peak Advisors, Inc
0.97%
$539K
As of Dec 31, 2025
Latest News
No related news yet